Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

This study has been terminated.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT00281879
First received: January 24, 2006
Last updated: July 2, 2012
Last verified: May 2012
  Purpose

RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacrolimus, or methylprednisolone may stop this from happening.

PURPOSE: This clinical trial is studying how well a donor stem cell transplant or donor white blood cell infusions work in treating patients with hematologic cancer.


Condition Intervention Phase
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Unusual Cancers of Childhood
Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: carmustine
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: methotrexate
Drug: methylprednisolone
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Lymphosarcoma Lymphoma, Small Cleaved-cell, Diffuse Multiple Myeloma Chronic Myeloproliferative Disorders Leukemia, Myeloid Chronic Myeloid Leukemia Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Hodgkin Lymphoma Acute Myelocytic Leukemia Acute Non Lymphoblastic Leukemia Myelodysplastic/myeloproliferative Disease Acute Myeloid Leukemia, Adult Follicular Lymphoma Hodgkin Lymphoma, Childhood B-cell Lymphomas Myelofibrosis Juvenile Myelomonocytic Leukemia Burkitt Lymphoma Lymphoma, Large-cell Lymphoma, Large-cell, Immunoblastic Plasmablastic Lymphoma Lymphoblastic Lymphoma Small Non-cleaved Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Chronic Myelomonocytic Leukemia Acute Lymphoblastic Leukemia, Childhood Chronic Neutrophilic Leukemia Hypereosinophilic Syndrome Acute Myeloid Leukemia, Childhood Mantle Cell Lymphoma Hairy Cell Leukemia Anaplastic Plasmacytoma
U.S. FDA Resources

Further study details as provided by OHSU Knight Cancer Institute:

Primary Outcome Measures:
  • Number of Participants With Disease Free Survival (DFS). [ Time Frame: Duration of the study; Up to 2 years ] [ Designated as safety issue: No ]

    Determine the effectiveness of unrelated donor allogeneic hematopoietic stem cells for transplantation after conditioning for the treatment of high-risk hematopoietic malignancies.

    Disease-free survival: The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer.



Enrollment: 200
Study Start Date: February 2006
Study Completion Date: March 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: cyclophosphamide
For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Radiation: radiation therapy
Radiation will be given to you 2 times a day for 3 or 4 days.
Active Comparator: Busulfan and Cyclophosphamide (Cytoxan) Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: busulfan
Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
Drug: cyclophosphamide
For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Active Comparator: BEAM Regimen
On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: carmustine
300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: cytarabine
400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
Drug: etoposide

Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.

Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload.

Drug: melphalan
140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Active Comparator: Low-Dose Fludarabine and TBI(for second stem cell donation)
A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: fludarabine phosphate

Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.

Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2.

Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Radiation: radiation therapy
Radiation will be given to you 2 times a day for 3 or 4 days.
Active Comparator: Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: busulfan
Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
Drug: cyclophosphamide
For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: fludarabine phosphate

Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.

Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2.

Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Active Comparator: ATG For Cord Blood Transplants
If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
Biological: anti-thymocyte globulin
Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
Other Name: ATG
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: methylprednisolone
Methyl-prednisolone is administered IV as a rapid infusion.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Procedure: umbilical cord blood transplantation
The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
Active Comparator: DLI (Donor Leukocyte Infusion)
Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Active Comparator: Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
Biological: filgrastim

Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.

Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Other Name: G-CSF
Drug: cyclophosphamide
For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Drug: cyclosporine
Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
Drug: etoposide

Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.

Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload.

Drug: methotrexate
Administered on days +1, +3, and +7.
Drug: mycophenolate mofetil
Mycophenolate may be used as a substitute for Methotrexate
Drug: tacrolimus
A drug used to decrease the risk of graft versus host disease (GvHD).
Other Name: FK-506
Procedure: peripheral blood stem cell transplantation
The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
Radiation: radiation therapy
Radiation will be given to you 2 times a day for 3 or 4 days.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following*:

    • Acute lymphoblastic leukemia in any disease phase

      • Patients with any of the following high-risk features are encouraged to enroll:

        • Philadelphia chromosome positive disease
        • L3 morphology, especially in the presence of t(8;14), t(8;22), or t(2;8)
        • Patients not in remission at day 28 of first induction
        • High LDH (i.e., ≥ 300 IU/mL at presentation)
        • Pre-B-cell, mixed lineage, or Burkitt's markers
        • Relapsed in the marrow while receiving continuous chemotherapy
        • Within 6 months after stopping chemotherapy
        • Relapse in one organ or extramedullary relapses in more than one organ while still receiving chemotherapy
    • Hodgkin's or non-Hodgkin's lymphoma beyond first complete remission (CR) or in first CR with features of high-risk disease, including, but not limited to:

      • Lymphoma not in CR after 3 courses of primary therapy
      • Patients with bulky disease at presentation, especially bulky mediastinal disease
      • Patients with LDH ≥ 300 IU/mL at presentation
      • Patients with extranodal disease
      • Patients with first remission within less than 1 year
      • Stage IV disease at presentation, especially with marrow involvement
      • Patients with high-intermediate or high International Index Scores
    • Acute myeloid leukemia (AML) meeting the following criteria:

      • Beyond first remission or high-risk disease in first CR
      • Required multiple courses of induction therapy to achieve a remission
      • Had residual leukemia on day 14-28 bone marrow examination after initial induction
      • Patients with any cytogenetic abnormality except inv 16 or t(8;21)
    • Chronic myelogenous leukemia in the chronic or early accelerated phase of the disease

      • Patients with blast crisis that can be induced back into chronic phase may be transplanted in second chronic phase
    • Myelodysplastic syndromes (MDS) meeting the following requirements:

      • Transfusion-dependent refractory anemia (RA), RA with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia (CMML)
      • Patients with MDS that present with or evolve to AML must be re-induced back to remission prior to initiating a search for an unrelated donor NOTE: *Patients with other hematologic malignancies not listed above, including diseases such as chronic lymphocytic leukemia (CLL), multiple myeloma, or rare pediatric malignancies, or patients who are felt to be at high-risk for relapse but who do not have features listed, may be allowed at the discretion of the investigator.
  • Must have failed prior stem cell transplantation
  • Must have a suitable unrelated allogeneic hematopoietic stem cell donor

    • A 5/6 match degree is acceptable for unrelated bone marrow donors
    • A 4/6 match degree is acceptable for unrelated cord blood units

PATIENT CHARACTERISTICS:

  • SWOG performance status (PS) 0-2 OR
  • Karnofsky PS 50-100% OR
  • Lansky PS 50-100%
  • Creatinine clearance ≥ 45 mL/min
  • Creatinine ≤ 2.5 mg/dL
  • Bilirubin ≤ 2 mg/dL (abnormally high liver function tests allowed if the only source for the elevation is due to lymphoma of the liver)
  • AST or ALT ≤ 2 times normal (abnormally high liver function tests allowed if the only source for the elevation is due to lymphoma of the liver)
  • No patients at high risk of veno-occlusive disease
  • Not pregnant or nursing
  • Negative serum pregnancy test
  • Fertile patients must use an effective contraceptive method
  • DLCO ≥ 50% of predicted
  • FEV_1/FVC ≥ 65% of predicted
  • No current congestive heart failure (CHF) and/or LVEF ≥ 45%
  • No myocardial infarction within the past 6 months
  • No unstable angina within the past 6 months
  • HIV negative
  • Life expectancy must not be limited by disease other than malignancy
  • No allergy to any chemotherapeutic agent included in the regimen

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00281879

Locations
United States, Oregon
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098
Sponsors and Collaborators
OHSU Knight Cancer Institute
Investigators
Study Chair: Richard Maziarz, MD OHSU Knight Cancer Institute
  More Information

No publications provided

Responsible Party: OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT00281879     History of Changes
Other Study ID Numbers: CDR0000452794, P30CA016058, OHSU-TPI-9695-L, OHSU-540
Study First Received: January 24, 2006
Results First Received: May 17, 2012
Last Updated: July 2, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by OHSU Knight Cancer Institute:
adult acute lymphoblastic leukemia in remission
L1 adult acute lymphoblastic leukemia
L2 adult acute lymphoblastic leukemia
L3 adult acute lymphoblastic leukemia
recurrent adult acute lymphoblastic leukemia
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
childhood acute lymphoblastic leukemia in remission
L1 childhood acute lymphoblastic leukemia
L2 childhood acute lymphoblastic leukemia
L3 childhood acute lymphoblastic leukemia
recurrent childhood acute lymphoblastic leukemia
recurrent adult Hodgkin lymphoma
recurrent/refractory childhood Hodgkin lymphoma
stage IV adult Hodgkin lymphoma
stage IV childhood Hodgkin lymphoma
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
childhood acute myeloid leukemia in remission
recurrent adult acute myeloid leukemia
recurrent childhood acute myeloid leukemia
myelodysplastic/myeloproliferative neoplasm, unclassifiable
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
secondary acute myeloid leukemia
refractory anemia with excess blasts in transformation

Additional relevant MeSH terms:
Neoplasms
Leukemia
Lymphoma
Lymphoma, Non-Hodgkin
Multiple Myeloma
Neoplasms, Plasma Cell
Plasmacytoma
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Lymphoma, Large-Cell, Immunoblastic
Hematologic Neoplasms
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions
Neoplasms by Site
Antilymphocyte Serum
Busulfan

ClinicalTrials.gov processed this record on August 26, 2014